Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Pain Clinical Trial

Official title:

A Randomized, Double-Blind Placebo-Controlled Exploration of a Topical Menadione-Containing Lotion to the Face for Prevention and Palliation of Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Discomfort and Psychological Distress

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01393821
• Other study ID #: MC10C9
• Secondary ID: NCI-2011-0104711
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 23, 2012
• Est. completion date: March 31, 2025

Study information

• Verified date: April 2024
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab. Menadione topical lotion may prevent rash or other skin discomfort and help alleviate psychological distress and pain in patients receiving treatment with panitumumab, erlotinib hydrochloride, or cetuximab

Description:

PRIMARY OBJECTIVES:

I. Explore the effectiveness of a menadione topical lotion to the face to prevent cutaneous and psychological discomfort from epidermal growth factor receptor (EGFR) inhibitors.

SECONDARY OBJECTIVES:

I. Explore the adverse event profile of a menadione topical lotion to the face to prevent rash from EGFR inhibitors.

II. Explore whether rash or adverse events worsen over a 4 week period after this 4-week intervention.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients apply menadione topical lotion twice daily (BID) for 28 days.

ARM II: Patients apply topical placebo lotion BID for 28 days.

After completion of study treatment, patients are followed up for 4 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 27
• Est. completion date: March 31, 2025
• Est. primary completion date: May 11, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older.

• Patient scheduled to start an epidermal growth factor receptor inhibitor (must be one of these three: panitumumab, erlotinib, cetuximab) within the next 3 days or patient has already started the epidermal growth factor receptor inhibitor but has not been on it for longer than 3 days and has no signs or symptoms potentially suggestive of EGFR inhibitor toxicity.

• Ability to reliably apply Menadione Topical Lotion / placebo twice a day to the face.

• Ability to complete questionnaire(s) by themselves or with assistance.

• Negative pregnancy test (serum or urine) done = 7 days prior to registration, for women of childbearing potential only.

• Willing to have photographs taken to assess rash.

Exclusion Criteria:

• Any active facial and/or chest rash, including adult acne, at the time of randomization.

• Cutaneous metastases, skin cancer, or a history of precancerous skin lesions involving the face and/or chest.

• Use of topical corticosteroids on the face and/or chest at the time of study entry or their anticipated use in the next 8 weeks.

• Any type of ongoing therapy for rash.

• Any of the following:

• Pregnant women

• Nursing women

• Men or women of childbearing potential who are unwilling to employ adequate contraception since this study involves agents that have known genotoxic, mutagenic and teratogenic effects

• Use of any antibiotic at the time of study or their anticipated use in the 8 weeks immediately following study enrollment.

Related Conditions & MeSH terms

• Dermatologic Complications
• Malignant Neoplasm
• Neoplasms
• Pain

Intervention

Drug:
• menadione topical lotion
Given topically

Other:
• placebo
Given topically
• questionnaire administration
Ancillary studies

Procedure:
• management of therapy complications
Given menadione topical lotion

Locations

Country	Name	City	State
United States	Mayo Clinic Campus in Arizona	Phoenix	Arizona
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to Week 4 Face Pain Score Measuring Cutaneous Discomfort	Change from baseline to Week 4 Face pain score measuring cutaneous discomfort. Face pain scale question ("How would you describe how your face feels?") with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.	From Baseline to Week 4
Secondary	The Number of Patients Experiencing Worst Toxicity	The number of patients experiencing treatment-related adverse events (toxicities) is reported below. The maximum grade toxicity (worst toxicity) is reported by arm.	Up to 8 weeks
Secondary	Long-term Cutaneous Discomfort as Measured by the Change From Baseline in Face Pain Scale at 4 Weeks (Treatment-regimen Estimand)	Least Squares mean (LS) of the Face Pain Scale change from baseline at week 4 was adjusted by treatment, week, race, gender, age (<=50 years/>50 years), and EGFR, via a MMRM analysis. Face pain scale question ("How would you describe how your face feels?") with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.	Baseline, 4 weeks
Secondary	Long-term Psychosocial Discomfort as Measured by the Change From Baseline in Psychological Distress Score at 4 Weeks (Treatment-regimen Estimand)	Least Squares mean (LS) of the Psychological Distress Score change from baseline at week 4 was adjusted by treatment, week, race, gender, age (<=50 years/>50 years), and EGFR, via a MMRM analysis. Psychological Distress question ("How often have you been bothered by embarrassment about your face?") with a 0-6 scale, where 0 = Never bothered and 6 = Always bothered.	Baseline, Week 4